What is chronic myelomonocytic leukaemia?
Chronic myelomonocytic leukaemia (CMML) is a rare blood cancer that starts in the bone marrow. It causes the body to make too many monocytes, a type of white blood cell that normally helps fight infection.
CMML sits between two groups of blood disorders. Like myelodysplastic syndromes (MDS), it makes faulty blood cells and can cause low blood counts. Like myeloproliferative neoplasms (MPN), it can produce too many cells and enlarge the spleen. Doctors therefore call it a myelodysplastic/myeloproliferative neoplasm.
CMML mainly affects older people, usually in their seventies, and is about twice as common in men.
Some people have mild disease that stays stable for years and needs only monitoring. Others have more active disease that causes symptoms, and in about 15-30% it changes into acute myeloid leukaemia (AML).
The only treatment that can cure CMML is a donor stem cell transplant, which is suitable for only a minority of patients. Other treatments aim to control the disease and improve quality of life.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Myelodysplastic/myeloproliferative neoplasm of the bone marrow |
| How common | About 4 people per million each year |
| Typical age | Median about 70-75; rare under 50 |
| Sex | About twice as common in men |
| Key blood finding | Persistent monocyte count of at least 0.5 x 10^9/L, making up 10% or more of white cells |
| Common gene changes | TET2, SRSF2, ASXL1, RUNX1, NRAS, KRAS, CBL |
| Main treatments | Monitoring, transfusions, hydroxyurea, azacitidine or decitabine, donor stem cell transplant |
| Outlook | Very variable; median survival about 2-4 years overall, many years for low-risk disease |
2. Types of CMML
Doctors classify CMML by the white cell count and by the number of immature cells (blasts), following the WHO 2022 classification.
| Classification | Definition | What it means |
|---|---|---|
| Myelodysplastic CMML (MD-CMML) | White cell count below 13 x 10^9/L | Mainly low blood counts, anaemia and infections |
| Myeloproliferative CMML (MP-CMML) | White cell count 13 x 10^9/L or more | High white cells, large spleen, sweats and weight loss; usually a poorer outlook |
| CMML-1 | Blasts under 5% in blood and under 10% in bone marrow | Lower risk |
| CMML-2 | Blasts 5-19% in blood or 10-19% in bone marrow | Higher risk of change to AML |
| AML | 20% or more blasts | No longer CMML; treated as acute leukaemia |
3. Causes and risk factors
CMML develops when a blood stem cell gathers acquired gene changes over time. These changes are found only in the blood cells and are not inherited.
| Factor | Notes |
|---|---|
| Age | The main risk factor; gene changes in blood cells build up with age (clonal haematopoiesis) |
| Male sex | Men are affected more often |
| Previous chemotherapy or radiotherapy | A small proportion are “therapy-related” |
| Chemical exposure | Benzene and some other chemicals may raise the risk of myeloid blood cancers |
| Smoking | Linked to myeloid blood cancers in general |
| Family history | Rarely relevant; inherited cases are very uncommon |
4. How does it look?
CMML is mainly seen in blood and bone marrow tests, but some people have visible signs.
4.1 On the body
| Feature | What it looks like |
|---|---|
| Pale skin | From anaemia |
| Bruises and tiny red spots (petechiae) | From low platelets |
| Swollen tummy | From a large spleen, felt under the left ribs |
| Skin lumps or rash | Red or purple patches or nodules when CMML cells enter the skin |
| Swollen gums or lymph nodes | Occasionally |
| Inflammatory signs | Joint swelling, rashes or inflamed blood vessels in people with autoimmune features |
4.2 Under the microscope
| Sample | What is seen |
|---|---|
| Blood film | Many monocytes, some immature; abnormal neutrophils with few granules or odd nuclei |
| Bone marrow | Busy marrow with increased monocytes and dysplasia (abnormal-looking cells) in one or more cell lines |
| Flow cytometry | An increase in “classical” monocytes (MO1 fraction above 94%) supports the diagnosis |
| Cytogenetics | Normal in many; trisomy 8, loss of Y or chromosome 7 changes in some |
5. Symptoms
Up to a third of people have no symptoms when CMML is found on a routine blood test.
5.1 Common symptoms
| Symptom | Why it happens |
|---|---|
| Tiredness and breathlessness | Anaemia (low red cells) |
| Infections | Faulty white cells |
| Bruising and bleeding | Low or poorly working platelets; nosebleeds and bleeding gums |
| Fullness or pain in the left upper tummy | Enlarged spleen |
| Feeling full quickly | The spleen presses on the stomach |
| Night sweats, fever, weight loss | More common in the myeloproliferative type |
5.2 Less common symptoms
| Symptom | Notes |
|---|---|
| Skin lesions | Leukaemia cutis, or inflammatory rashes such as Sweet syndrome |
| Joint pain and swelling | Autoimmune or inflammatory conditions occur in about 1 in 5 |
| Bone pain | Uncommon |
| Fluid around the heart or lungs | Rare |
5.3 When to see a doctor
See a doctor if you have unexplained tiredness, frequent infections, easy bruising, night sweats or weight loss. A simple blood count is the first test. Symptoms that get worse quickly, such as rising fevers or new bleeding, need urgent review.
6. Diagnosis
| Test | Why it is done |
|---|---|
| Full blood count | Shows persistent monocytosis, and often anaemia or low platelets |
| Repeat counts | Monocytosis must last at least three months |
| Blood film | Looks at the shape of cells and counts blasts |
| Bone marrow aspirate and biopsy | Confirms the diagnosis, counts blasts and checks for fibrosis |
| Cytogenetics | Looks for chromosome changes |
| Gene panel (NGS) | Finds mutations such as TET2, SRSF2 and ASXL1; supports diagnosis and estimates risk |
| BCR::ABL1 and other tests | Rule out chronic myeloid leukaemia and other conditions with similar counts |
| Tests for other causes | Infections, inflammation and other cancers can raise monocytes and must be excluded |
Other causes of a raised monocyte count
A high monocyte count is much more often caused by something other than CMML. These causes are ruled out before the diagnosis is made.
| Cause | Examples |
|---|---|
| Infections | Tuberculosis, endocarditis, some viral and fungal infections |
| Inflammation | Rheumatoid arthritis, lupus, inflammatory bowel disease, sarcoidosis |
| Recovery of the bone marrow | After chemotherapy or a severe infection |
| Medicines | Steroids and growth factor injections |
| Other blood cancers | Chronic myeloid leukaemia, myeloproliferative neoplasms, acute monocytic leukaemia |
| Other cancers | Some solid tumours and lymphomas |
7. Risk assessment
Doctors use scoring systems to estimate how CMML is likely to behave.
| Score | What it includes |
|---|---|
| CPSS | CMML type (CMML-1 or 2), MD or MP type, chromosome risk and transfusion need |
| CPSS-Mol | Adds gene mutations (ASXL1, NRAS, RUNX1, SETBP1) to the CPSS |
| Mayo molecular model | Uses ASXL1 mutation, haemoglobin, platelets, monocyte count and immature cells in blood |
Low-risk patients may live many years without treatment. High-risk patients have a greater chance of AML and are assessed early for transplant.
8. Treatment
The choice of treatment depends on the type of CMML, the risk score, symptoms, age and general fitness. Because most patients are older and many have other health problems, the aim is often to control symptoms and keep a good quality of life rather than to cure the disease.
Younger, fitter patients with higher-risk disease should be referred early to a transplant centre, so that a donor search can start while the disease is controlled.
8.1 Overview of options
| Treatment | Who it is for | Notes |
|---|---|---|
| Watch and wait | Low-risk, no symptoms | Regular blood counts |
| Blood and platelet transfusions | Anaemia or bleeding | Iron levels are monitored |
| Erythropoiesis-stimulating agents | Anaemia in lower-risk, MD-type disease | Injections such as epoetin may reduce transfusions |
| Hydroxyurea (hydroxycarbamide) | High white count, big spleen or sweats in MP-CMML | Tablets that lower counts |
| Azacitidine or decitabine | Higher-risk disease or troublesome symptoms | Hypomethylating agents; decitabine is also available as a tablet with cedazuridine |
| Allogeneic stem cell transplant | Fit patients with higher-risk disease, usually under about 70-75 | The only potentially curative treatment; carries serious risks |
| Clinical trials | Any stage | Targeted and new drugs are being studied |
8.2 Supportive care
| Area | What helps |
|---|---|
| Infection prevention | Vaccinations (avoid live vaccines), prompt treatment of fevers |
| Bleeding | Avoid aspirin unless advised; platelet transfusion if needed |
| Inflammatory problems | Steroids or other immune treatments |
| Fatigue | Pacing activities, gentle exercise, treating anaemia |
9. Side effects of treatment
| Treatment | Possible effects |
|---|---|
| Hydroxyurea | Low counts, mouth or leg ulcers, skin changes |
| Azacitidine or decitabine | Low blood counts, infections, nausea, constipation, injection-site redness |
| Stem cell transplant | Severe infections, graft-versus-host disease, organ damage and a risk of death from the treatment itself |
Complications that need urgent care
| Complication | Warning signs |
|---|---|
| Serious infection | Fever, shivering, feeling very unwell; needs same-day antibiotics |
| Bleeding | Nosebleeds that will not stop, blood in urine or stools, many new bruises |
| Spleen problems | Sudden pain under the left ribs or in the left shoulder |
| Change to AML | Rapidly worsening blood counts, rising blasts, new tiredness or infections |
| Leukostasis | Very high white count causing headache, breathlessness or confusion |
10. Outlook
| Situation | Approximate median survival |
|---|---|
| Low-risk CMML | Often more than 5-6 years |
| Intermediate risk | About 2-3 years |
| High-risk CMML | About 1-1.5 years |
| After stem cell transplant | About a third to a half are alive long term |
| Change to AML | Happens in about 15-30% over time |
These are averages and depend on the scoring system used. Many people with low-risk CMML die of other causes.
11. Living with CMML
CMML is often a long-term condition. Regular blood tests let the team spot changes early.
Tell your team straight away about fever of 38 C or higher, bleeding, new lumps, or sudden pain under the left ribs, which can mean the spleen is enlarging.
Keep active where you can, eat well and stay up to date with flu, COVID-19 and pneumococcal vaccines. Support from a specialist nurse and patient groups helps people and their families cope with uncertainty.
If you need regular transfusions, ask about your iron levels, as repeated transfusions can lead to iron overload. Keep a record of your blood counts and any treatments, and carry information about your condition when travelling.
12. Frequently asked questions
| Question | Answer |
|---|---|
| Is CMML the same as chronic myeloid leukaemia (CML)? | No. CML has the BCR::ABL1 (Philadelphia) gene change and is treated with tablets called TKIs. CMML does not |
| Is it inherited? | No. The gene changes happen during life, in the blood cells only |
| Do I need treatment straight away? | Not always. Many people with low-risk CMML only need monitoring |
| Can it be cured? | Only with a donor stem cell transplant; other treatments control the disease |
| Will it turn into acute leukaemia? | Some cases do, especially CMML-2 and high-risk disease, but many never do |
13. Questions to ask your care team
- Do I have MD-CMML or MP-CMML, and is it CMML-1 or CMML-2?
- What is my risk score, and which gene changes were found?
- Do I need treatment now, or can we monitor my blood counts?
- Am I a candidate for a stem cell transplant, and should I be referred to a transplant centre?
- What signs should make me call the hospital straight away?
- Is there a clinical trial I could join?
Bringing a family member or friend to appointments, and keeping a list of your blood results, can help you follow how the disease is changing.
Resources
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- Orazi, A. et al. (2023) ‘International Consensus Classification for myeloid neoplasms at-a-glance’, American Journal of Hematology, 98(1), pp. 6-10.
- Patnaik, M.M. and Tefferi, A. (2024) ‘Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management’, American Journal of Hematology, 99(6), pp. 1142-1165.
- Such, E. et al. (2013) ‘Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia’, Blood, 121(15), pp. 3005-3015.
- Elena, C. et al. (2016) ‘Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia’, Blood, 128(10), pp. 1408-1417.
- Padron, E. et al. (2015) ‘An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies’, Blood Cancer Journal, 5(7), e333.
- Duchmann, M. et al. (2018) ‘Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents’, EBioMedicine, 31, pp. 174-181.
- National Cancer Institute (2026) Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.